Question-and-Answer Session
Operator
(Operator Instructions) Your first question comes from the line of Geoff Meacham - JPMorgan.
Analyst for Geoff Meacham - JPMorgan
I just have a couple of quick questions for you on what to expect for ipilimumab at ASCO in terms of what types of efficacy metrics can we expect? And then outside of ipilimumab, can you give us an idea of any other data that we could expect at ASCO?
Howard H. Pien
The abstracts for the ASCO have been submitted. We don’t know which ones have been accepted yet. It’s more than a dozen abstracts that have been submitted and we are waiting to hear from ASCO as to just precisely what the program is going to be and what are the various opportunities for the data to be presented and showcased.
Analyst for Geoff Meacham - JPMorgan
Can you give us an idea of some of the potential efficacy metrics that we would see there?
Howard H. Pien
No. Except to say what we have said before, we will have the entirety of the data set including the specific numbers on the response rates, as well as the various ways that the response rates beyond the conventional definition of the 24-week efficacy can be fleshed out to demonstrate the profile of ipilimumab’s utility in this potential indication.
Analyst for Geoff Meacham - JPMorgan
It looks like prostate cancer might be one of the more advanced indications for ipilimumab outside of melanoma. I am just wondering if you can talk a little bit about the trial design. What are the endpoints there? What types of patients are you going to be targeting, and what combinations would you potentially be using?
Howard H. Pien
We have not yet come to a conclusion on all of these important parameters that would define the clinical development program with BMS. But as I said before these discussions are ongoing in such a way that we have the confidence to say that we will have a milestone this year on the Phase 3 development program initiating for prostate.
Operator
And your next question comes from the line of Mark Monane - Needham.
Mark Monane - Needham
Interestingly, the data you’ve presented, I know you’re working on submitting an application, but it seems that the Phase 3 in front-line melanoma might be available at the end of this year or the beginning of next year, and therefore two applications may be rather contiguous in time.
- To read the full transcript on Seeking Alpha, click here »
